Dermatol. praxi. 2013;7(4):180-182

Severe case of ulcerative skin lesions

MUDr.Jana Čechovičová, MUDr.Lubomír Drlík
Dermatovenerologické oddělení, Šumperská nemocnice, a. s.

Calciphylaxis is characterized by ischemic ulcerative skin lesions and high mortality. It develops as a complication of renal insufficiency

in many cases. Pyoderma gangrenosum belongs to neutrophilic dermatosis and it’s associated with systemic diseases. Authors report

two cases of these serious ulcerative skin lesions, their clinical and histological features, diagnostic and therapy possibilities.

Keywords: calciphylaxis, hemodialysis, pyoderma gangrenosum

Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čechovičová J, Drlík L. Severe case of ulcerative skin lesions. Dermatol. praxi. 2013;7(4):180-182.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Somach SC. Calciphylaxis (calcific uremic arteriolopathy). In: Morgan MB, Smoller BR, Somach SC. Deadly Dermatologic Diseases. Clinicopathologic Atlas and Text. New York: Springer, 2007: 167-172.
    2. Weenig RH, Sewell LD, Davis MPD, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007; 56: 569-579. Go to original source... Go to PubMed...
    3. Burns T, Breathnach S, Cox N, et al. Rook´s Textbook of Dermatology, 8th edition, Wiley - Blackwell, Singapore, 2012, p. 4 9.47-49.48, 50.64-50.74, ISBN 978-1-4051-6169-5.
    4. Wollina U. Pyoderma gangrenosum - a review. Orphanet J Rare Dis 2007; 2: 19. Go to original source... Go to PubMed...
    5. Jackson JM, Callen JP. Pyoderma gangrenosum: an expert commentary. Expert Rev Dermatol 2006; 1: 391-400. Go to original source...
    6. Oka M. Pyoderma gangrenosum and interleukin-8. Br J Dermatol 2007; 157: 1279-1281. Go to original source... Go to PubMed...
    7. Rifkin BS, Perazella MA. Calcific uremic arteriolopathy (calciphylaxis). Mayo Clin Proc 2006; 81: 9. Go to original source... Go to PubMed...
    8. Horáková M, Pock L, Bureš I, et al. Kalcifylaxe s kožními ulceracemi - popis případu. Čes.-slov. Derm 2012; 87(3): 98-101.
    9. Callen JP. Neutrophilic dermatoses. Dermatol Clin 2002; 20: 409-419. Go to original source... Go to PubMed...
    10. Santos M, Talhari C, Rabelo RF, et al. Pyoderma gangrenosum: a clinical manifestation of difficult diagnosis. An Bras Dermatos. 2011; 86(1): 153-156. Go to original source... Go to PubMed...
    11. Kosari P, Feldman SR. Letter: Treatment-resistant pyoderma gangrenosum. Dermatol Online J. 2012; 18(4): 8. Go to original source...
    12. Powell FC, Su WPD. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996; 34: 395-409. Go to original source... Go to PubMed...
    13. Weenig RH, Davis MPD, Dahl PR, Su WPD. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 2002; 347: 1412-1418. Go to original source... Go to PubMed...
    14. Pastor N, Betlloch I, Pascua JC, et al. Pyoderma gangrenosum treated with anti - TNF alpha therapy (etanercept). Clin Exp Dermatol 2005; 31: 152-153. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.